

AngioDynamics to Hold Fiscal First Quarter Financial Results Conference Call on Thursday, October 7, 2004

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Oct. 1, 2004--AngioDynamics, Inc. (Nasdaq:ANGO) today announced that the company will release first quarter results on Thursday, October 7, 2004 after market close.

Eamonn P. Hobbs, president and chief executive officer, and Joseph G. Gerardi, chief financial officer, will host an investment community conference call beginning at 4:30 p.m. Eastern Time on October 7th to discuss these results and to answer questions.

To participate in the live call by telephone, please dial 888-804-7108 from the U.S., or for international callers, please dial 706-634-1250.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' web site at http://investor.angiodynamics.com/. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the Web site for 14 days. A telephone replay will be available from 7:30 p.m. Eastern Time October 7, 2004 through 11:59 p.m. Eastern Time on October 9 by dialing 888-642-1687 (domestic) or 706-645-9291 (international) and entering conference ID number 1232115.

About AngioDynamics

AngioDynamics, Inc. designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. AngioDynamics is a majority-owned subsidiary of E-Z-EM, Inc. (AMEX:EZM), a leading manufacturer of contrast agents for gastrointestinal radiology.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations.

CONTACT: AngioDynamics, Inc.

Lisa Donegan, 800-772-6446 x370

www.AngioDynamics.com

or

Investor Relations Contacts:

Lippert/Heilshorn & Associates, Inc.

Kim Sutton Golodetz (kgolodetz@lhai.com)

Shayne Payne (spayne@lhai.com)

212-838-3777

Bruce Voss (bvoss@lhai.com)

310-691-7100

SOURCE: AngioDynamics, Inc.